The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …

Liver cancer is the third most common cause of cancer-related mortality worldwide, with over
780,000 deaths in 2018. About 90% of liver cancer cases are hepatocellular carcinoma …

Abstract Anti-programmed cell death-1 (PD-1) therapy exerts beneficial effects in a limited
population of cancer patients. Therefore, more accurate diagnostics to predict the efficacy of …

Introduction The PACIFIC regimen of consolidation therapy with the programmed cell death-
ligand 1 inhibitor durvalumab after definitive concurrent chemoradiation therapy has …

Background: Immunotherapy has been successful in treating advanced melanoma, but a
large proportion of patients do not respond to the treatment with immune checkpoint …

Immune checkpoint inhibitors (ICI) have been applied in treating advanced hepatocellular
carcinoma (aHCC) patients, but few patients exhibit stable and lasting responses. Moreover …

Background Clinical trials of novel therapies for the treatment of ulcerative colitis (UC) may
benefit from immune cell profiling, however implementation of this methodology is limited in …

Due to the lack of biomarkers predictive of response to atezolizumab–bevacizumab, the
standard of care for advanced HCC, we analyzed baseline and early on‐treatment variation …

Introduction The discovery of immune checkpoints and the development of their specific
inhibitors was acclaimed as a major breakthrough in cancer therapy. However, only a limited …

Programmed cell death 1 ligand 2 (PD-L2), a member of the B7 immune checkpoint protein
family, emerges as a crucial player in immune modulation. Despite its functional overlap with …